Renexxion plans to file new drug application (NDA) with the Food and Drug Administration (FDA) using future Phase 3 results ROSCREA, Ireland and ...
Jefferies Global Healthcare Conference 2026 June 4, 2026 9:55 AM EDTCompany ParticipantsPeter Griffith - Executive VP & ...
MarketBeat on MSN
Apogee Therapeutics readies Zumi for phase 3 with Blackstone backing
Key Points Interested in Apogee Therapeutics Inc.? Here are five stocks we like better. Apogee Therapeutics plans to advance ...
Eosinophilic AE-COPD is associated with a lower risk for major adverse cardiovascular events (MACE) compared with noneosinophilic AE-COPD.
Stanford Medicine researchers and their colleagues found that a new drug, obexelimab, significantly reduces the risk of ...
Amgen Inc. upgraded to cautious Buy: pipeline growth drivers, margin upside, and risk/reward near lows. Click for this AMGN ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results